Alzheimer’s Disease Can Be Spared by Nonsteroidal Anti-Inflammatory Drugs
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is characterized by deposits of amyloid-β protein (Aβ) in brain which become foci of inflammation. Neurons are destroyed by this inflammatory process, leading to the cognitive deficits which define AD clinical onset. Epidemiological studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) can ameliorate this destructive process if they are started well before clinical signs develop. Biomarker studies indicate that the disease process starts at least a decade before cognitive deficits appear. This pre-clinical onset explains the NSAID effect. It also opens a window of opportunity for preventive treatment that can be met with a simple diagnostic test. Salivary levels of Aβ 42 may fulfill that need. They can be measured by a simple ELISA test we have developed using commercially available reagents. By this ELISA test, normal controls, who are not at risk for AD, have levels of Aβ 42 close to 20 pg/ml. AD cases, as well as high level controls, secrete levels in the range of 40–85 pg/ml. Widespread application of this test to detect high level controls, followed by NSAID consumption, could substantially reduce the prevalence of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Self-citationMcGeer, P. L., Itagaki, S., Tago, H., & McGeer, E. G. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90696-3 · Cited by 836 · cited 1×
“We reported in 1988 that AD brains showed activated microglia expressing HLA-DR, an immunology marker previously thought to be exclusively associated with peripheral leukocytes [1].”
BackgroundSelf-citationBuchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664
The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
McGeer, P. L., & McGeer, E. G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1177-7 · Cited by 467 · cited 1×
“A theoretical construct suggests the development of AD goes through 6 phases, each with decreasing opportunity for therapeutic intervention [9].”
BackgroundSelf-citationPrediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease
Prestia, A., Caroli, A., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C. E., Wall, A. E., Carter, S. F., Schöll, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182872830 · Cited by 184
Cited by
Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines
Rea, I. M., Gibson, D. S., McGilligan, V., McNerlan, S. E., Alexander, H. D., & Ross, O. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00586 · Cited by 1,267
Jin, X., Liu, M., Zhang, D., Zhong, X., Du, K., Qian, P., Yao, W., Gao, H., & Wei, M. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13086 · Cited by 383
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Ashton, N. J., Ide, M., Zetterberg, H., & Blennow, K. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00168-1 · Cited by 89
Anti-inflammatory role of gold nanoparticles in the prevention and treatment of Alzheimer's disease
Aili, M., Zhou, K., Zhan, J., Zheng, H., & Luo, F. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb01023f · Cited by 80
DNA Hypomethylation in Blood Links B3GALT4 and ZADH2 to Alzheimer’s Disease
Madrid, A., Hogan, K. J., Papale, L. A., Clark, L. R., Asthana, S., Johnson, S. C., & Alisch, R. S. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180592 · Cited by 77
Metadata
- Authors
- McGeer, P. L., Guo, J. P., Lee, M., Kennedy, K., & McGeer, E. G.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-10-30
- Volume
- 62
- Issue
- 3
- Pages
- 1219-1222
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2765544398
- Cited by
- 76
- References
- 6
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.